Shionogi Receives MHLW's Approval for Xofluza's sNDA to Treat Post-Exposure Prophylaxis of Influenza Virus Infection
Shots:
- The approval is based on P-III BLOCKSTONE study assessing Xofluza (baloxavir marboxil- 10/20mg) vs PBO in patients in household members aged ≥12yrs. who was living with someone with an influenza infection confirmed by a rapid influenza diagnostic test
- Result: The proportion of household members who developed influenza (1.9% vs 13.6%); well tolerated with no new safety signals identified
- Xofluza inhibits the cap-dependent endonuclease in the PA protein and is a single-dose oral treatment for influenza which is different from all other currently available antiviral treatments
Ref: Shionogi | Image: Businesswire
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com